Literature DB >> 27173463

Increased postprandial apolipoprotein B-48 level after a test meal in diabetic patients: A multicenter, cross-sectional study.

Cheol-Young Park1, Joong-Yeol Park2, Jongwon Choi3, Dae Jung Kim4, Kyong Soo Park5, Kun-Ho Yoon6, Moon-Kyu Lee7, Sung-Woo Park8.   

Abstract

OBJECTIVE: To evaluate plasma apolipoprotein B (ApoB)-48 concentrations among Korean diabetic subjects with normal to moderately high levels of low-density-lipoprotein cholesterol (LDL-C).
METHODS: This multicenter, cross-sectional study included subjects with LDL-C levels between 100 and 160mg/dL who had not been treated with a lipid-lowering agent for over 6weeks prior to baseline. Blood tests to assess lipid-profile parameters were conducted in both fasting and postprandial states. This study compared ApoB-48 and other lipid-profile parameters in diabetic and nondiabetic subjects.
RESULTS: Of the 93 subjects enrolled, 88 (42 diabetic; 46 nondiabetic) completed the study. Significantly higher mean incremental area under curve (0-6h; iAUC0-6h) of postprandial ApoB-48 levels was noted among diabetic subjects than nondiabetic subjects (p=0.0078). The mean postprandial ApoB-48 peak level was higher in diabetic subjects; however, the difference was not statistically significant. The fasting ApoB-48 level was similar in both groups: 5.9 (3.5) in diabetics and 7.3 (5.8) in nondiabetics (p=0.18). The iAUC0-6h of postprandial total cholesterol (TC), triglyceride (TG), LDL-C, non-high-density-lipoprotein cholesterol (non-HDL-C), ApoB-100, and remnant cholesterol was similar in both groups. The ApoB-48 level was moderately correlated with TG and non-HDL-C for both groups (p<0.05).
CONCLUSION: Without lipid-lowering treatment, the postprandial increment in ApoB-48 level was significantly higher in Korean diabetic subjects compared with nondiabetic subjects, irrespective of similar LDL-C levels.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apolipoprotein B-48; Cross-sectional study; Diabetic; Post-prandial

Mesh:

Substances:

Year:  2016        PMID: 27173463     DOI: 10.1016/j.metabol.2016.02.008

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  4 in total

1.  Remnant cholesterol for the detection of glucose metabolic states in patients with coronary heart disease angina pectoris.

Authors:  Yang Wang; Yijia Liu; Rongrong Yang; Zhu Li; Jinyu Su; Tong Yang; Mei Ma; Guangwei Pan; Xianliang Wang; Lin Li; Chunquan Yu
Journal:  Acta Diabetol       Date:  2022-07-23       Impact factor: 4.087

Review 2.  Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding.

Authors:  Allan D Sniderman; Patrick Couture; Seth S Martin; Jacqueline DeGraaf; Patrick R Lawler; William C Cromwell; John T Wilkins; George Thanassoulis
Journal:  J Lipid Res       Date:  2018-05-16       Impact factor: 5.922

3.  Comparison of calculated remnant lipoprotein cholesterol levels with levels directly measured by nuclear magnetic resonance.

Authors:  Jin Chen; Jie Kuang; Xiaoyu Tang; Ling Mao; Xin Guo; Qin Luo; Daoquan Peng; Bilian Yu
Journal:  Lipids Health Dis       Date:  2020-06-10       Impact factor: 3.876

4.  Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study.

Authors:  Jiwoo Lee; You-Cheol Hwang; Woo Je Lee; Jong Chul Won; Kee-Ho Song; Cheol-Young Park; Kyu Jeung Ahn; Joong-Yeol Park
Journal:  Diabetes Ther       Date:  2020-02-17       Impact factor: 2.945

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.